SMALL MOLECULE INHIBITORS OF IL-6 AND USES THEREOF
    3.
    发明申请
    SMALL MOLECULE INHIBITORS OF IL-6 AND USES THEREOF 审中-公开
    IL-6的小分子抑制剂及其用途

    公开(公告)号:US20140315956A1

    公开(公告)日:2014-10-23

    申请号:US14235591

    申请日:2012-07-29

    摘要: In one aspect, the invention relates to substituted 2-(1H-indol-3-yl)ethanol analogs and substituted 3,3a,8,8a-tetrahydro-2H-furo[2,3-b]indole analogs, derivatives thereof, and related compounds, which are useful as inhibitors of IL-6 mediated activation of the Jak2/STAT3 pathway; synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating disorders of uncontrolled cellular proliferation associated with a IL6 dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

    摘要翻译: 一方面,本发明涉及取代的2-(1H-吲哚-3-基)乙醇类似物和取代的3,3a,8,8a-四氢-2H-呋喃并[2,3-b]吲哚类似物,其衍生物, 和相关化合物,其可用作IL-6介导的Jak2 / STAT3途径的激活的抑制剂; 制备化合物的合成方法; 包含该化合物的药物组合物; 以及使用所述化合物和组合物治疗与IL6功能障碍相关的不受控制的细胞增殖紊乱的方法。 该摘要旨在作为用于在特定技术中进行搜索的扫描工具,而不意在限制本发明。

    PP2A REGULATORY SUBUNIT MODIFICATION IN DISEASE
    5.
    发明申请
    PP2A REGULATORY SUBUNIT MODIFICATION IN DISEASE 审中-公开
    PP2A调节疾病中的亚细胞调节

    公开(公告)号:US20140031291A1

    公开(公告)日:2014-01-30

    申请号:US13945753

    申请日:2013-07-18

    IPC分类号: C12Q1/68

    CPC分类号: C12Q1/6883 C12Q2600/158

    摘要: Disclosed herein are methods for the diagnosis, detection, and treatment of cardiovascular disease and symptoms thereof in a subject. Disclosed herein are methods of diagnosing ischemic heart disease, non-ischemic heart disease, myocardial infarction, tachy-pacing induced non-ischemic heart disease, heart failure, and catecholaminergic-induced arrhythmia and symptoms thereof in a subject. Disclosed herein are methods of screening the efficacy of a pharmaceutical agent for treating cardiovascular disease and symptoms thereof in a subject. Disclosed herein are methods of identifying a subject eligible for a cardiovascular disease treatment clinical trial

    摘要翻译: 本文公开了用于诊断,检测和治疗受试者心血管疾病及其症状的方法。 本文公开了诊断受试者中缺血性心脏病,非缺血性心脏病,心肌梗死,快速起搏诱导的非缺血性心脏病,心力衰竭和儿茶酚胺能诱导的心律失常及其症状的方法。 本文公开了筛选用于治疗受试者的心血管疾病及其症状的药剂的功效的方法。 本文公开了鉴定符合心血管疾病治疗临床试验的受试者的方法

    Compositions and methods for cancer detection and treatment
    6.
    发明授权
    Compositions and methods for cancer detection and treatment 有权
    癌症检测和治疗的组成和方法

    公开(公告)号:US09044432B2

    公开(公告)日:2015-06-02

    申请号:US13518828

    申请日:2010-12-22

    摘要: Disclosed herein are compositions and methods for cancer detection and treatment. Compounds that inhibit PRMT5 are contemplated, as are pharmaceutical compositions comprising a therapeutically effective amount of at least one PRMT5 inhibitor. In some embodiments pharmaceutical compositions further comprising at least one HDAC inhibitor are contemplated. Methods of treating disorders in a mammal by inhibiting PRMT5 by administering to a mammal, a therapeutically effective amount of a PRMT5 inhibitor are also disclosed.

    摘要翻译: 本文公开了用于癌症检测和治疗的组合物和方法。 预期抑制PRMT5的化合物,以及包含治疗有效量的至少一种PRMT5抑制剂的药物组合物。 在一些实施方案中,预期还包含至少一种HDAC抑制剂的药物组合物。 还公开了通过向哺乳动物施用治疗有效量的PRMT5抑制剂来抑制PRMT5来治疗哺乳动物疾病的方法。

    Compositions and Methods for Cancer Detection and Treatment
    7.
    发明申请
    Compositions and Methods for Cancer Detection and Treatment 有权
    癌症检测和治疗的组合和方法

    公开(公告)号:US20130059892A1

    公开(公告)日:2013-03-07

    申请号:US13518828

    申请日:2010-12-22

    摘要: Disclosed herein are compositions and methods for cancer detection and treatment. Compounds that inhibit PRMT5 are contemplated, as are pharmaceutical compositions comprising a therapeutically effective amount of at least one PRMT5 inhibitor. In some embodiments pharmaceutical compositions further comprising at least one HDAC inhibitor are contemplated. Methods of treating disorders in a mammal by inhibiting PRMT5 by administering to a mammal, a therapeutically effective amount of a PRMT5 inhibitor are also disclosed.

    摘要翻译: 本文公开了用于癌症检测和治疗的组合物和方法。 预期抑制PRMT5的化合物,以及包含治疗有效量的至少一种PRMT5抑制剂的药物组合物。 在一些实施方案中,预期还包含至少一种HDAC抑制剂的药物组合物。 还公开了通过向哺乳动物施用治疗有效量的PRMT5抑制剂来抑制PRMT5来治疗哺乳动物疾病的方法。